Role of measuring the expression levels of a proliferation-inducing ligand and its receptors by real-time fluorescence quantitative method in children with lymphoma
Chen, J.; He, Z.-x.; Zhang, D.-l.; Xian, H.; Cai, W.
Zhonghua Yi Xue Za Zhi 90(36): 2541-2544
2010
ISSN/ISBN: 0376-2491 PMID: 21092459 Document Number: 647866
To investigate the role of a real-time fluorescence quantitative polymerase chain reaction (PCR) in measuring the expression levels of a proliferation-inducing ligand and its receptors expression levels in peripheral blood of children with lymphoma. real-time fluorescence quantitative PCR was used to detect the expression levels of a proliferation-inducing ligand and its receptors in patients with Hodgkin disease (n = 10) or non-Hodgkin lymphoma (n = 37) and healthy control (n = 40). The correlation between the mRNA levels of a proliferation-inducing ligand and its receptors and differential stage of malignant lymphoma was analyzed. the results of 47 samples showed that the levels of proliferation-inducing ligand, B cell maturation antigen, transmembrane activator and CAML interactor in the peripheral blood of lymphoma in children were significantly higher than those in normal children (1.13 ± 0.09 vs 0.41 ± 0.09, 1.22 ± 0.11 vs 0.43 ± 0.10, 0.89 ± 0.12 vs 0.35 ± 0.08, all P < 0.05). The level of a proliferation-inducing ligand and its receptors had no significant difference between Hodgkin disease and non-Hodgkin lymphoma (P > 0.05). The level of a proliferation-inducing ligand in I-II stage (0.88 ± 0.06, 0.90 ± 0.08) of malignant lymphoma in children was significantly lower than that in III-IV stage (1.21 ± 0.09, 1.23 ± 0.09, P < 0.05) while the level of its receptors between various stages showed no difference (P > 0.05). the real-time fluorescence quantitative PCR has a high sensitivity and reproducibility. A proliferation-inducing ligand may play a great role in the development and progression of malignant lymphoma in children through its receptors of B cell maturation antigen, transmembrane activator and CAML interactor. A proliferation-inducing ligand and its receptors can be established as target molecules for early diagnosis and anti-cancer therapy.